Harvard Bioscience Management

Management criteria checks 1/4

Harvard Bioscience's CEO is Jim Green, appointed in Jul 2019, has a tenure of 4.75 years. total yearly compensation is $2.39M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 4.33% of the company’s shares, worth €6.36M. The average tenure of the management team and the board of directors is 1.7 years and 6.5 years respectively.

Key information

Jim Green

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	24.5%
CEO tenure	4.8yrs
CEO ownership	4.3%
Management average tenure	1.7yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Green's remuneration changed compared to Harvard Bioscience's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$586k	-US$3m
Sep 30 2023	n/a	n/a	-US$3m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$2m	US$574k	-US$10m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$3m	US$574k	-US$288k
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$3m	US$574k	-US$8m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$3m	US$265k	-US$5m
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	US$432k
Mar 31 2019	n/a	n/a	-US$819k
Dec 31 2018	US$153k	n/a	-US$4m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$7m
Dec 31 2017	US$129k	n/a	-US$2m

Compensation vs Market: Jim's total compensation ($USD2.39M) is above average for companies of similar size in the German market ($USD691.02K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Green (65 yo)

4.8yrs

Tenure

US$2,392,240

Compensation

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Green	President	4.8yrs	US$2.39m	4.33% $ 6.4m
Jennifer Cote	CFO & Treasurer	1.3yrs	US$571.27k	0.097% $ 142.5k
David Balcom	Senior Vice President of Operations	1.8yrs	no data	no data
John Fry	Chief Legal Counsel & Corporation Secretary	1.7yrs	no data	no data
Ryan Wallace	Senior Vice President of Global Sales	less than a year	no data	no data
Lori Packer	Vice President of Global People Operations	no data	no data	no data

1.7yrs

Average Tenure

62yo

Average Age

Experienced Management: HBI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
James Green	President	9yrs	US$2.39m	4.33% $ 6.4m
Alan Edrick	Independent Director	4.6yrs	US$213.09k	0.47% $ 685.2k
Bertrand Loy	Lead Independent Director	9.4yrs	US$223.06k	1.08% $ 1.6m
Thomas Loewald	Independent Director	6.5yrs	US$205.45k	0.52% $ 757.6k
Katherine Eade	Independent Director	6.5yrs	US$198.09k	0.55% $ 811.1k

6.5yrs

Average Tenure

57yo

Average Age

Experienced Board: HBI's board of directors are considered experienced (6.5 years average tenure).

Harvard Bioscience Management

Management criteria checks 1/4

Key information

Recent management updates

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

President recently bought €101k worth of stock

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

President recently bought €100k worth of stock

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought €72k worth of stock

Recent updates

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.081 loss per share (vs US$0.23 loss in FY 2022)

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Third quarter 2023 earnings released: US$0.029 loss per share (vs US$0.082 loss in 3Q 2022)

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President recently bought €101k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.023 loss per share (vs US$0.059 profit in 2Q 2022)

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 24% undervalued after recent price drop

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

Now 22% undervalued

Now 20% undervalued

Now 21% undervalued

President recently bought €100k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.007 loss in FY 2021)

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought €72k worth of stock

Forecast breakeven date pushed back to 2024

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

President recently bought €125k worth of stock

Forecast breakeven date pushed back to 2023

Second quarter 2022 earnings released: EPS: US$0.059 (vs US$0.01 loss in 2Q 2021)

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought €107k worth of stock

President recently bought €140k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Forecast to breakeven in 2021

President recently sold €329k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Harvard Bioscience, Inc. Files A Motion to Vacate the Suffolk Superior Court’S Order Allowing Plaintiff’S Motion for Sanctions

Independent Director has left the company

Harvard Bioscience, Inc. Provides Financial Guidance for 2021

First quarter 2021 earnings released: US$0.017 loss per share (vs US$0.12 loss in 1Q 2020)

President recently sold €175k worth of stock

New 90-day high: €4.30

Full year 2020 earnings released: US$0.20 loss per share (vs US$0.12 loss in FY 2019)

Revenue beats expectations

Harvard Bioscience, Inc. to Report Q4, 2020 Results on Mar 10, 2021

New 90-day high: €3.76

New 90-day high: €3.44

New 90-day high: €3.24

Revenue beats expectations